BIOMAT Database Logo BIOMAT Database Logo

[Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer]. 1998

S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
Dept. of Surgery, Kawasaki Medical School.

Sequential chemotherapy with methotrexate and 5-fluorouracil (MTX/5-FU) for advanced gastric cancer was given 29 patients. The procedure consisted of weekly MTX 100 mg/m2 (i.v.) followed three hours later by 5-FU 600 mg/m2 (i.v.) with leucovorin rescue on each of the following two days. Nine of 28 patients (32.1%) showed partial response to this treatment. Response rates were 28.6% in the 21 cases with poorly differentiated adenocarcinoma and 42.9% in the 7 cases with well- or moderately-differentiated adenocarcinoma. This procedure was especially effective for primary lesions (PR 9/20: 45%) and lymphnode metastases (CR 4 + PR 4, 8/17: 47.1%). Side effects were mild leukopenia and G-I symptoms such as nausea, diarrhea and loss of appetite, except in 1 patient who died of severe myelosuppression with sepsis. We concluded that sequential MTX/5-FU therapy is fairly effective and the adjuvant chemotherapy of choice for advanced or recurrent gastric cancer with not only poorly differentiated adenocarcinoma but also well- or moderately-differentiated adenocarcinoma.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
[Sequential chemotherapy with low-dose methotrexate and 5-fluorouracil in advanced gastric cancer].
August 1985, Gan no rinsho. Japan journal of cancer clinics,
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer.
November 1986, Cancer treatment reports,
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
February 2010, Journal of cancer research and clinical oncology,
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
[Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].
August 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
Sequential combination chemotherapy with methotrexate and 5-fluorouracil in advanced colorectal carcinoma.
December 1984, Tumori,
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer].
August 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
[A new sequential chemotherapy of methotrexate with 5-fluorouracil against advanced colo-rectal cancer].
April 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil.
February 1991, Journal of chemotherapy (Florence, Italy),
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma.
January 1989, Cancer chemotherapy and pharmacology,
S Iwamoto, and M Kimoto, and T Mure, and E Onuma, and Y Yamamoto, and K Iki, and K Yoshida, and Y Tadaoka, and T Majima, and S Kawasaki, and T Kubozoe, and T Tsunoda
Neoadjuvant chemotherapy with sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin for locally advanced bladder cancer.
January 2002, Oncology,
Copied contents to your clipboard!